key: cord-1017397-7u62y543 authors: Jeffrey Yang, Chi-Fu title: Commentary: Thoracic Surgery During the COVID-19 Pandemic: Recommendations from China date: 2020-07-16 journal: J Thorac Cardiovasc Surg DOI: 10.1016/j.jtcvs.2020.07.040 sha: 909f4e295fc8875e6cb0c86e26baf84a01c74d1f doc_id: 1017397 cord_uid: 7u62y543 nan million cases and 130,000 deaths in all 50 states. 1 Guidelines from the U.S. and Europe have been published to aid treatment decision-making for thoracic cancers during the pandemic. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Most of these guidelines have been written for hospitals and clinicians who still have capacity to take care of cancer patients and have not been completely overwhelmed by COVID-19. These guidelines have generally recommended delaying surgery for select instances of early-stage disease, and, for more advanced disease, proceeding with traditional curative-intent treatment consistent with pre-COVID standard-of-care recommendations. Consideration of other nonoperative treatments (e.g. stereotactic ablative radiotherapy for lung cancer or endoscopic therapy for esophageal cancer) have also been proposed. In "peak" stages of the epidemic, when hospital resources are severely strained, thoracic surgery is recommended only for patients with emergent clinical conditions, such as perforated esophageal cancers, that, left untreated, would result in death within hours or days. 2, 15 While these guidelines are useful, they have been written largely by American and European authors, and speak to the American and European experience. To date, there have been very few recommendations from Asia. [16] [17] [18] In this issue of the Journal, Chen and colleagues, 19 all expert thoracic surgeons from high-volume thoracic surgery centers across China, make several recommendations for the treatment of thoracic surgical disease during the COVID-19 pandemic, in light of their experiences in China. The editorial is an important one, and the authors should be commended for their efforts. Several of the author's recommendations are similar to those by American and European authors. For example, the authors call for "the cessation of all thoracic surgeries for GGO-like lung adenocarcinoma with a diameter of less than 30 mm during the COVID-19." No specification of time interval accompanies this recommendation, but other American and European groups have similarly commented on postponing surgery for nodules with ground-glass opacities or lepidic adenocarcinomas for at least 3-6 months. 2, 4, 20 The authors also call for "enhancing preoperative induction treatment" in a manner similar to that of the U.S. and Europe. The authors recommend that patients with operable stage IIIA N2 disease undergo induction therapy first, as opposed to surgery. This would allow patients to avoid undergoing an operation during potential COVID-19 hospitalization peaks. The standardof-care in the U.S. and Europe is to give induction therapy first, followed by surgery for operable stage IIIA-N2 NSCLC. 21, 22 In China, it can be common in centers to perform surgery first, followed by adjuvant chemotherapy for stage IIIA-N2 disease. 23, 24 The authors' recommendation to proceed with induction therapy first, followed by surgery, is likely aimed more at a Chinese audience, to urge more Chinese thoracic surgeons to consider use of induction therapy during the pandemic. Other practices in China differ from those at many U.S. hospitals. Through correspondence with Dr. Chen, I learned that most COVID patients are taken care of in separate "COVID" or "infectious disease hospitals" as soon as the diagnosis is made. As Dr. Chen wrote, "if tracheostomies and chest tubes are needed, ENT (tracheostomies) and thoracic surgeons (chest tubes) from other hospitals will be temporarily transferred to that hospital. And some infectious disease hospitals also have their own surgeons to take care of patients, such as at Ditan Hospital in Beijing." Another key difference between China and the U.S. is the degree of testing and observation each patient receives prior to undergoing thoracic surgery. For patients who need surgery, presumably for more advanced disease, the authors recommend that "patients should be observed in a transitional ward for two weeks." The authors note that during this observational period, patients should be tested for COVID-19 by nasal swab two weeks before surgery and that within one week of surgery, patients should have a "chest CT for COVID-19 screening…C-reactive protein, procalcitonin, and influenza A and B examination." There is some variation as to how these recommendations are implemented. In correspondence, I learned from Dr. Chen that at his institution, the practice is that "All patients from other parts of the country will be isolated in designated places [e.g. hotels] for two weeks before they can visit our outpatient clinic. And prior to their admission [to the hospital for surgery], they will have throat swab test, antibody and blood test, as well as CT examination, to confirm they are COVID-19 negative." High-volume centers in China also generally seem to be better-equipped and/or prioritize wearing protective personal equipment to a greater degree than their U.S. counterparts. For example, Dr. Chen noted that at his outpatient clinic, every provider wears N95 respirators, isolation gowns, gloves and face shields when interacting with patients, regardless of whether the patients are suspected to have COVID. In my own experience, and anecdotally from speaking with colleagues, this is not common practice in the U.S. This past week in clinic, at my own institution, I was required to only wear a surgical mask. The editorial by Chen and colleagues raises a number of points that are important for thoracic surgeons and oncologists treating lung and esophageal cancer patients to consider. There are additional questions that need to be discussed as well. For example, what if the pandemic continues with no abatement for another 1-2 years-how would practices change in that situation? How do we think about care for mesothelioma patients? Does definitive chemoradiation, which requires multiple outpatient visits, lead to less risk of exposure to COVID to both patients and healthcare workers when compared to surgery, which requires no outpatient visit (with telemedicine) and typically 1 inpatient hospital stay? In addition, it is worth noting, that recommendations made by both the authors, and by American and European groups, are principally based on clinical expertise and opinion. More actual data to drive policy and practice is needed as well. To date, there have been only a few studies that have reported outcomes of patients with lung cancer and COVID-19: 8 from China, 25-32 1 from Denmark 33 , 3 from Italy, 34-36 2 from Spain, 37, 38 and 2 from the U.S.. 39, 40 All of these studies had only a few patients: the largest of these studies involved 22 patients. 28 It will be critical for thoracic surgeons worldwide to actively report their experiences with COVID-19 patients, and engage in dialogue and collaboration. Case reports are helpful, but more analyses of institutional data, national registries, or COVID-19 open-access data 41 are needed. Meaningful multiinstitutional collaborations enable studies with enough statistical power to facilitate such analyses. These analyses, in turn, can provide the groundwork for meaningful, guidelinechanging recommendations. Such recommendations will be desperately needed during this first COVID-19 wave, and in future pandemic waves. COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement from Thoracic Surgery Outcomes Research Network, The Society of Thoracic Surgeons and The American Association for Thoracic Surgery Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic Term Recommendations for Non-Small Cell Lung Cancer Management During the COVID-19 Pandemic Accessed 10 Management of Lung Cancer During the COVID-19 Pandemic Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic ESMO management and treatment adapted recommendations in the COVID-19 era: Lung cancer Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere Lung cancer and mesothelioma service guidance during the COVID-19 pandemic Elective lung cancer surgery in the COVID-19 era: how do we do it? Tumori Management of surgical lung cancer patients during the COVID-19 pandemic in the financially and resource strained Greek health care system Management of the airway and lung isolation for thoracic surgery during the COVID-19 pandemic: Recommendations for clinical practice endorsed by the Association for Cardiothoracic Anaesthesia and Critical Care and the Society for Cardiothoracic Surgery in Great Britain and Ireland Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Elective Case Triage Guidelines for Surgical Care Thoracic Cancer Surgery Clinical recommendations on lung cancer management during the COVID-19 pandemic. Thorac Cancer Preliminary recommendations for lung surgery during COVID-19 epidemic period Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19 Insights from China: Improving Thoracic Surgery Outcomes During the COVID-19 Pandemic Elective Case Triage Guidelines for Surgical Care Thoracic Cancer Surgery Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines Practice Guidelines in Oncology: Non-small Cell Lung Cancer (Version 3.2020) Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. The Journal of thoracic and cardiovascular surgery Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery. The Journal of thoracic and cardiovascular surgery Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19 Coronavirus Disease 2019 in the Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery Department in Wuhan, People's Republic of China Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2 Clinical and Transmission Characteristics of Covid-19 -A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department Early Appearance of Coronavirus Disease 2019 Associated Pulmonary Infiltrates During Daily Radiotherapy Imaging for Lung Cancer A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region Covid-19 and lung cancer: A greater fatality rate? Lung Cancer A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection? Lung Cancer Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020. 41. NIH. Open-Access Data and Computational Resources to Address COVID-19